Novartis: Novartis' Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G
Approximately half of C3G patients progress to kidney failure within ten years of diagnosis
Read full article »
Novartis is a Switzerland-based multinational medicines company that researches and develops generic and pharmaceutical products for the healthcare industry.
Read more